SynthesisClinical neurology and neurosurgery2025
Efficacy and safety of surpass evolve flow diverters: A systematic review and meta-analysis.
Synthesis in Clinical neurology and neurosurgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative outcomes of surpass streamline and evolve flow diverters in intracranial aneurysms: a comprehensive systematic review and meta-analysis of location, size, and morphology.Neurosurgical review · 2026Pooled it
- Surpass evolve flow diverter in intracranial aneurysms: results from a single-center cohort with extended follow-up.Acta neurochirurgica · 2026Article
- Postoperative acute ultra-early fish mouthing of a Surpass Evolve flow diverter leading to ischemic complication.Radiology case reports · 2026Article
- Treatment outcome of flow-diversion with Surpass Evolve stent for unruptured intracranial aneurysms: Predictors of poor occlusion.Journal of cerebrovascular and endovascular neurosurgery · 2026Article
- Factors Associated with Aneurysm Occlusion after Flow Diverter Treatment.Journal of neuroendovascular therapy · 2026Review
- Photocrosslinked dual-network hydrogel for sutureless corneal stromal lenticule lmplantation.Frontiers in bioengineering and biotechnology · 2026Article
- Efficacy and safety of flow diverters in basilar artery aneurysms: a single-center retrospective cohort study.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo provide cumulative evidence on the safety and efficacy of the Surpass Evolve Flow Diverters (SE-FDs) in treating intracranial aneurysms.
methodsPubMed, Scopus, Embase, and Web of Science were searched until May, 2024. The primary efficacy endpoint was complete occlusion rate, and the safety endpoints included rate of different complications and mortality. Data is pooled and reported with 95 % confidence intervals (CIs) using random-effect models. A meta-regression analysis was performed to assess the potential effects of confounding factors on study endpoints.
resultsEleven studies with 690 patients and 757 aneurysms were included. There was moderate risk of bias in all studies. With a median follow-up of 243 days, the complete occlusion rate was 67.1 % (95 %CI: 57.3-75.5 %, I
conclusionsSE-FD is effective for treating intracranial aneurysms, with moderate efficacy compared to other devices and an acceptable rate of complications. Larger aneurysm size predicts lower occlusion rates. The lack of controlled trials warrants further research to explore the efficacy and safety of SE-FDs in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.